Leadership & People

C-suite changes at Relief Therapeutics and promotions at Black Diamond Therapeutics are among recent executive changes in the industry. Meanwhile, new directors were appointed at Adagio Therapeutics, OKYO Pharma and Tenaya Therapeutics, among others.

Industry leaders including Sanofi's ex-CEO and the chiefs of Sun, Lupin, Glenmark, Dr Reddy’s and Cipla discuss how India could leapfrog its pharma R&D efforts. Could the South Korea model or a hybrid approach including bringing back top talent bolster the country’s efforts to emerge as a global innovation hot spot?

Management outlined its growth strategy to investors, highlighting plans to file 14 novel drugs with more than $1bn in peak sales by 2025.

Janssen global oncology therapeutic area head Peter Lebowitz talked to Scrip about the company's next big ambitions in lung, bladder and prostate cancer.

C-suite changes at Appili Therapeutics and promotions at Collmune are among recent executive changes in the industry. Meanwhile, new directors were appointed at Diurnal Group, Artios Pharma and Verastem, among others.

Despite 23 years at Biogen assisting in the development of several drugs, Sandrock's legacy will be tied to Alzheimer’s drug Aduhelm.

The cardiologist seeking another term as FDA commissioner has been working in the pharma industry since leaving the post, but Senators have tended not to  question nominee's work history extensively during previous confirmation hearings.

Aurobindo will formalize a succession plan in early December as managing director N Govindarajan, who has spent over a decade at the company, is set to move on. Meanwhile, though a settlement has been reached for generic Revlimid launch plans, development of a COVID-19 vaccine with partner Vaxxinity has hit a major roadblock

C-suite changes at Acorda Therapeutics and promotions at GT Biopharma are among recent executive changes in the industry. Meanwhile, new directors were appointed at Caribou Bioscience, Defence Therapeutics and Beam Therapeutics, among others.

As the Swiss major took a deep dive on its projects for diseases ranging from pancreatic cancer to osteoarthritis and kidney disease, development head John Tsai spoke about how the firm's digital capabilities are helping those programs advance quicker.

New leaders in investor relations at Johnson & Johnson and promotions at Vivanza Biosciences are among recent executive changes in the industry. Meanwhile, new directors were appointed at Bioventus and AC Immune, among others.

The France-headquartered company has brought forward its carbon neutral goal, making it one of the sector’s most proactive companies.